Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6444567 | 0.88 | TSHR (0.56) | TSHRTDP1ALDH1A1NPSR1MEN1 | |
| SCHEMBL6446598 | 0.88 | TSHR (0.56) | TSHRTDP1ALDH1A1NPSR1MEN1 | |
| SCHEMBL6446602 | 0.88 | TSHR (0.56) | TSHRTDP1ALDH1A1NPSR1MEN1 | |
| SCHEMBL6443369 | 0.82 | TSHR (0.58) | TSHRTDP1ALDH1A1NPSR1MAPT | |
| SCHEMBL6443366 | 0.82 | TSHR (0.58) | TSHRTDP1ALDH1A1NPSR1MAPT | |
| SCHEMBL6443372 | 0.82 | TSHR (0.58) | TSHRTDP1ALDH1A1NPSR1MAPT | |
| SCHEMBL739486 | 0.77 | TSHR (0.66) | TSHRTDP1ALDH1A1NPSR1MEN1 | |
| SCHEMBL6443412 | 0.76 | TSHR (0.57) | TSHRTDP1ALDH1A1NPSR1MAPT | |
| SCHEMBL6138380 | 0.75 | TSHR (0.59) | TSHRTDP1ALDH1A1NPSR1TLR2 | |
| SCHEMBL13689024 | 0.75 | TSHR (0.59) | TSHRTDP1ALDH1A1NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | TSHR 2585/4885TDP1 758/4885ALDH1A1 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.